+86-27-65522453 sales@sun-shinechem.com

Pacritinib(SB1518)

Catalog No.: 122941
Cas No.: 937272-79-2
Purity : 98% by HPLC 
122941 - Pacritinib(SB1518) | CAS 937272-79-2

Catalog number : 122941

CAS number : 937272-79-2

分子式 : C28H32N4O3 

分子量 : 472.579 

Iupac 化学名称 : (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 

Smile : C1(C2=NC(NC3=CC=C(OCCN4CCCC4)C(COC/C=C/COC5)=C3)=NC=C2)=CC5=CC=C1

InChiKey : HWXVIOGONBBTBY-ONEGZZNKSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词SB1518;SB 1518;SB-1518;Pacritinib;ONX 0803, BAX 2201 
英文同义词SB1518;SB 1518;SB-1518;Pacritinib;ONX 0803, BAX 2201 
分子式C28H32N4O3 
分子量472.579 
外观pale-yellow powder 
纯度98% by HPLC 
可溶性Soluble in DMSO 
存储-20 ºC for 3 years 
运输条件Shipped under ambient temperature 
SmileC1(C2=NC(NC3=CC=C(OCCN4CCCC4)C(COC/C=C/COC5)=C3)=NC=C2)=CC5=CC=C1
InChiKeyHWXVIOGONBBTBY-ONEGZZNKSA-N
InChiInChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
Coming soon.

Pacritinib (puh-CRIT-i-nib) is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Activating mutations of JAK2 are implicated in certain blood-related cancers, including myeloproliferative neoplasms (MPNs), leukemia and certain solid tumors. FLT3 is a gene commonly found mutated in patients with acute myeloid leukemia (AML). Pacritinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis and may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

 

937272-79-2 - Request Bulk Quote

×
937272-79-2 - Request Bulk Quote
Change